ER positive

About

Biomarker type: Protein expression

Marker: Estrogen receptor (ER)

Unit: status

Equality: =

Value: Positive

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (4) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (4) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (4) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (2) HC (1) ER positive, HER2-negative, PIK3CA oncogenic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) AKT1 oncogenic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) AKT1 oncogenic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Elacestrant
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (2) ER positive Invasive Breast Carcinoma Fulvestrant
FDA (2) ER positive, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (4) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (4) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (4) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (4) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (2) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (4) HC (1) ER positive, HER2-negative, PIK3CA oncogenic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
FDA (4) HC (1) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
HC (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
HC (1) ER positive, HER2-positive Invasive Breast Carcinoma Neratinib
HC (1) ER positive, HER2-negative, PIK3CA amplification Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (2) ER positive, HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (2) ER positive, HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (2) ER positive, HER2-ultralow Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (2) ER positive, HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (2) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Imlunestrant
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Exemestane, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Exemestane, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Letrozole, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Letrozole, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Vepdegestrant